Skip to main content

Overview of the Molecular Characteristics of PYLARIFY

Interview with the Innovators
PET/CT Imaging in Prostate Cancer Patients
Videos — January 26, 2022
Steven Rowe, MD, PhD
Radiology and Radiological Science
Johns Hopkins Medicine,
Baltimore, MD

Dr Steven Rowe details the molecular characteristics of PYLARIFY® (piflufolastat F 18) and the OSPREY and CONDOR pivotal trials, which led to the FDA approval of PYLARIFY®.

Related Items

Patients Are at the Heart of Everything We Do
January 2024, Vol 14, No 1
Interview with the Innovators
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
By Nadia Harbeck, MD, PhD
Videos
Interview with the Innovators
New Developments on Prognostic Markers for Patients With Early Breast Cancer
By Nadia Harbeck, MD, PhD
Videos
Interview with the Innovators
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
By Nadia Harbeck, MD, PhD
Videos
Interview with the Innovators